EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Direct questions

2. Can clinics still prescribe compounded semaglutide or tirzepatide after the shortages ended?

Dose Diligence research deskSection 01 · Page 2 of 34Last updated 17 Nov 2026

Not on the assumption that shortage-era permissions continue. Prescribing a compounded product does not independently establish that its manufacture, distribution and dispensing qualify for federal exemptions. FDA’s retrieved policy page states that semaglutide and tirzepatide are not on its shortage list or 503B bulks list. (fda.gov)

Relevant milestones include:

DateVerified developmentProcurement implication
December 19, 2024FDA issued a new determination resolving the tirzepatide injection shortageDo not rely on an earlier shortage-era justification. (fda.gov)
February 21, 2025FDA determined the semaglutide injection shortage was resolvedReview any continuing arrangement against post-shortage requirements. (fda.gov)
April 30, 2026FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listA proposal is not a final determination; nor is it permission to compound. (fda.gov)

For an actual proposal, obtain a dated explanation of the statutory pathway, exact formulation, ingredient eligibility and applicable copying restrictions. Require counsel to distinguish a statutory exemption from enforcement discretion.

Unresolved in this review: the live shortage-database entries could not be retrieved. Recheck them immediately before approving any arrangement whose justification depends on shortage status.

Explore the table row by row

A working view of the research

December 19, 2024

Verified development
FDA issued a new determination resolving the tirzepatide injection shortage
Procurement implication
Do not rely on an earlier shortage-era justification. (fda.gov)

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. fda.gov · Source 2 ↗https://www.fda.gov/media/185526/download?attachment=&utm_source=openai
  3. fda.gov · Source 3 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list?utm_source=openai
Section sources →